•
Dec 31, 2023

Acadia Healthcare Q4 2023 Earnings Report

Acadia Healthcare reported strong Q4 2023 results, demonstrating impressive revenue and EBITDA growth, driven by solid execution and strategic investments.

Key Takeaways

Acadia Healthcare's Q4 2023 performance showcased strong revenue growth of 10.0% year-over-year, driven by a 10.3% increase in same-facility revenue. The company continued its growth strategy through facility expansions, de novo facilities, and joint ventures. Acadia provided full year and first quarter 2024 guidance, reflecting confidence in continued growth and profitability.

Revenue totaled $742.8 million, a 10.0% increase year-over-year.

Same facility revenue increased by 10.3% compared to Q4 2022.

Net income attributable to Acadia was $57.7 million, or $0.63 per diluted share.

Adjusted income attributable to Acadia was $78.3 million, or $0.85 per diluted share.

Total Revenue
$743M
Previous year: $675M
+10.0%
EPS
$0.87
Previous year: $0.74
+17.6%
US Same Facility Revenue Growth
10.3%
Previous year: 9.4%
+9.6%
US Same Facility Patient Days Growth
2.9%
Previous year: 4%
-27.5%
US Rev. per Patient Day Growth
7.1%
Previous year: 5.2%
+36.5%
Gross Profit
$171M
Previous year: $284M
-39.9%
Cash and Equivalents
$100M
Previous year: $97.6M
+2.5%
Free Cash Flow
-$22.4M
Previous year: $26.2M
-185.6%
Total Assets
$5.36B
Previous year: $4.99B
+7.4%

Acadia Healthcare

Acadia Healthcare

Forward Guidance

Acadia established financial guidance for 2024, with revenue projected between $3.18 and $3.25 billion and adjusted earnings per diluted share between $3.40 and $3.70. For the first quarter of 2024, revenue is expected to be between $775 and $785 million, with adjusted earnings per diluted share between $0.78 and $0.83.

Positive Outlook

  • Revenue between $3.18 to $3.25 billion
  • Adjusted EBITDA between $730 to $770 million
  • Adjusted earnings per diluted share between $3.40 to $3.70
  • Operating cash flows between $525 to $575 million
  • Total bed additions of approximately 1,200 beds

Challenges Ahead

  • Interest expense between $110 to $120 million
  • Tax rate between 24.5% to 25.5%
  • Depreciation and amortization expense between $150 to $160 million
  • Stock compensation expense between $40 to $45 million
  • Expansion capital expenditures between $425 to $475 million